Abstract: Provided are methods for diagnosing or selecting a mammal in need of a stimulant ADHD drug, conducting a non-specific electro-dermal responses (EDAs) analysis and/or an auditory sustained attention (ASAT) analysis on the mammal and administering or adjusting the dose of a stimulant ADHD drug to be administered to the mammal.

Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.

Abstract: Disclosed herein is desloratadine for use in the treatment and/or prophylactic treatment of lung cancer, prostate cancer, pancreatic cancer, gastric cancer, kidney cancer, ovarian cancer, colorectal cancer, Hodgins's disease, bladder cancer, liver cancer, and/or nasopharyngeal cancer.

Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Abstract: This invention relates to the field of atrophic scarring and describes methods of using small molecule chemical compounds and formulations thereof to reduce the appearance of atrophic acne scarring. These methods and formulations are contemplated for cosmetic uses of reducing the appearance of acne scarring, or for potential therapeutic uses of reducing, reversing, or treating acne scarring. Also contemplated are use of these compounds to reduce the appearance of atrophic scarring or for potential therapeutic uses of reducing, reversing, or treating atrophic scarring.

Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain from 1 mg/ml to 300 mg/ml of chloroquine, hydroxychloroquine, or pharmaceutically acceptable salt(s) thereof and a solvent that is one or more of a glycerin, a propylene glycol, and a polyethylene glycol. Such formulations are free of added water and contain an amount of the the solvent is present sufficient to result in the chloroquine, hydroxychloroquine, or pharmaceutically acceptable salt thereof being in the solution phase of the formulation.

Abstract: Methods and composition for treating or preventing a lung infection, or related symptoms, caused by a bacterium, fungus, and/or virus using an effective amount of tafenoquine are disclosed. Methods and compositions for treating or preventing a lung infection in a human that is infected with SARS-CoV-2 using tafenoquine are disclosed.

Abstract: The present invention includes methods for treating a proliferative disorder comprising administering a therapeutically effective amount of crenolanib or a salt thereof in combination with pharmaceutical agent targeting apoptosis pathway proteins wherein the crenolanib and other agent are provided at least one of sequentially or concomitantly in a subject for use in the treatment of the proliferative disease, wherein the subject is a human subject.

Abstract: Embodiments provide for methods of treatment for subjects suffering from a condition/disorder or disease for which the renin-angiotensin-aldosterone system (RAAS) plays at least some role. In one example, a method comprises administering to the subject an effective amount of one or more of an angiotensin receptor AT2R antagonist for a duration sufficient to elicit a desired response in the subject suffering from pancreatic cancer. The administering acts to reduce proliferation of tumor cells associated with the pancreatic cancer.

Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Abstract: A pharmaceutical composition and method for treating opioid overdose, opioid dependency, and xylazine exposure is disclosed, utilizing an aqueous solution of sodium chloride. This solution contains active ingredients such as naloxone and yohimbine in specific concentrations, with naloxone targeting opioid overdose and yohimbine aimed at counteracting Xylazine effects. In various embodiments, additional components like tolazoline and different buffers can be included. The disclosure introduces a unique delivery system that features a capsule with a vibrating mesh atomizer for efficient administration. Specifically, for yohimbine, a dual-reservoir capsule design facilitates controlled mixing with diluents or buffers. The administration of this pharmaceutical composition can be achieved through multiple methods, including intramuscular, intravenous, and atomized routes. The atomizing device incorporates a removable cap and a resilient air bladder, ensuring effective drug delivery.

Abstract: Provided herein are drug products adapted for nasal delivery comprising a device and a pharmaceutical composition comprising an opioid receptor antagonist or unit doses thereof, pharmaceutical compositions comprising an opioid receptor antagonist, and methods of use and preparation thereof.

Abstract: Provided herein are methods for inhibiting ALPK1 kinase activity using a compound of Formula I, and compositions and methods for therapy, for example in treating Kawasaki Disease.

Abstract: This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.

Abstract: Disclosed are methods of treating myeloproliferative neoplasms, diseases, and disorders.

Abstract: Disclosed herein is a method for the treatment or delay of progression of cancer in a subject, comprising administering to the subject in need thereof a BTK inhibitor, for example, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with a PI3K? inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.

Abstract: This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be administered intermittently at a time interval of at least one week.

Abstract: Described are compounds of formula (I), or pharmaceutically acceptable salts thereof: (I) that are useful for control of protein expression with eDHFR tags and methods of controlling protein expression with such compounds, as well as kits comprising the compounds.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of lung cancer with a pyrimidinylaminobenzene, e.g., a compound of Formula (I).

Abstract: Provided are pharmaceutical compositions which include a mixture of a lipophilic active pharmaceutical ingredient such as nilotinib, a hydrophilic polymer, one or more surfactants, and optionally an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising the active pharmaceutical ingredient.

Abstract: The present invention relates to a solid dispersion of a HER2 inhibitor and a pharmaceutically acceptable dispersion carrier. Also provided herein are pharmaceutical compositions and kits comprising the solid dispersion, uses thereof, particularly in the treatment and/or prevention of cancer, and processes of preparing the solid dispersion.

Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors, and compositions, nanoformulations and methods for treating diseases or disorders (e.g., breast cancer, pancreatic cancer, lung cancer, and lymphoma) with PBK inhibitors or composition thereof. Disclosed herein is a composition comprising: an effective amount of a PI3K inhibitor or a pharmaceutically acceptable salt thereof; and an albumin nanoparticle.

Abstract: A stable formulation comprising tetrodotoxin, and/or a derivative, analog, or a pharmaceutically acceptable salt thereof, wherein the formulation comprises the tetrodotoxin component and one or more solvents, pH adjusting agents, buffering agents, and stabilizing agents.

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Abstract: The present application discloses a compound of formula (I) as a USP1 inhibitor, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof, and use thereof in prevention or treatment of diseases associated with USP1.

Abstract: This invention relates to a method of treating damage to the central nervous system, comprising administering a pharmaceutically-effective amount of a CCR5 antagonist, and a pharmaceutically effective amount of an AQP4 antagonist, or pharmaceutically acceptable salts thereof.

Abstract: Methods that increase bioavailability and/or efficacy of a therapeutic agent for treatment of an ocular surface disorder, cornea disorder, or anterior chamber disorder are provided. In particular, tear production is increased by administration of an electrical stimulus, ultrasound stimulus, and/or a drug such as an nAChR?7 agonist (e.g., varenicline, (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, 5-{(E)-2-[(3R)-pyrrolidin-3-yl]vinyl}pyrimidine, or (R,E)-5-(2-pyrrolidine-3-yl)vinyl)pyrimidine). The primary therapeutic agents provided include recombinant adeno-associated virus (AAV) vectors expressing a therapeutic gene product (e.g., a biologic drug). Related compositions methods of use are also provided.

Abstract: In general, the invention relates to pharmaceutical compositions comprising a 5-xHT2C agonist, and methods of treating conditions associated with central hypoventilation including administering a 5-HT2C agonist.

Abstract: The present disclosure relates to a composition for treating osteoarthritis or eliminating senescent cells, including K-7174 that targets zinc finger MIZ domain-containing protein 1 (Zmiz1) as an active ingredient, wherein suppression of overexpression of Zmiz1 found in osteoarthritis-induced joint tissues or mice as well as suppression of expression, due to binding between K-7174 and GATA whose expression is induced by the Zmiz1 overexpression, of joint destructing factors (Mmp3, Cox2) and senescence cell promoting factors (Glb1, p16) whose expressions are increased upon the overexpression have shown effects of decreasing the progression of osteoarthritis and promoting elimination of senescent cells, such that it is possible to provide a composition including the K-7174 as an active ingredient as a treatment for osteoarthritis or an agent for eliminating senescent cells.

Abstract: The present disclosure relates to methods for treating cystic fibrosis with compositions comprising an effective amount of certain N-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that reversibly inhibit dipeptidyl peptidase 1 (DPP1) activity. Methods provided herein are useful for increasing the lung function in a patient, and/or improving the patient's quality of life (QOL) assessed by the cystic fibrosis questionnaire-revised (CFQ-R). In one embodiment, the compound of Formula (I) is brensocatib.

Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of certain oncogenic proteins.

Abstract: Compounds and methods for inhibiting Nrf2 by activating KEAP1.

Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by AXL.

Abstract: Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m2/g, methods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m2/g, methods for making such particles, and methods for-their use as therapeutics.

Abstract: The present disclosure provides a method of treating or reducing the symptoms of congenital adrenal hypoplasia in a human patient, comprising administering to the human patient in need thereof a therapeutically effective amount of vamorolone or a salt or polymorph thereof.

Abstract: Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.

Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans streptococci, Enterococcus, or combinations thereof.

Abstract: The present invention provides pharmaceutical compositions and methods of treating Covid-19 infectious disease. The present invention also provides pharmaceutical compositions and methods of prophylaxis or prophylactic treatment of Covid-19 infectious disease. The said methods involve administering compositions comprising therapeutically effective amount of Cannabidiol thereby causing enhancement/augmentation of innate immunity of the patient/mammal/human.

Abstract: A phytocannabinoid formulation comprises an amount of at least about 90 percent by weight of one or more phytocannabinoid. The phytocannabinoid formulation further comprises an amount of at least about 0.1 percent by weight of a plurality of lipophilic molecules including at least one saturated straight chain C14-C20 fatty acid and at least one unsaturated ?-6 C18-C22 fatty acid. The phytocannabinoid formulation also includes an amount of at least about 0.1 percent by weight of at least one bioflavonoid.

Abstract: The invention relates to compositions and formulations for the treatment of disorders of the gastrointestinal (GI) tract. Also provided are methods for treating, preventing, and/or alleviating disorders of the GI tract.

Abstract: The present invention relates to the use of cannabidivarin (CBDV) for the treatment of seizures associated with canine epilepsy. In a further embodiment the CBDV used is in the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 1.5% (w/w).

Abstract: A method of reducing symptoms of a neurodegenerative disease comprising administering an effective amount of cannabidiol to a subject in need thereof to improved cognitive function and ameliorated the pathophysiology of the neurodegenerative disease.

Abstract: The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ?27 kg/m2.

Abstract: Methods of treatment for psoriasis, and compositions for use in such methods are provided, utilizing repositioned drugs identified as anti-psoriasis agents.

Abstract: The present disclosure relates to a nucleoside compound and an application thereof in the treatment of feline infectious peritonitis. The compound belongs to the GS-441524 analogues. The compound has little toxic effect on normal cat cells, while it has a significant inhibitory effect on feline coronavirus. The compound can be used to prepare feline coronavirus inhibitors for the treatment of feline infectious peritonitis. It has the advantages of good curative effect, high safety, and excellent water solubility, which makes it easier to be absorbed.

Abstract: Novel SARS-CoV-2 inhibitors with dual targeting activity against both the viral RdRp and Mpro and host TMPRSS2 protease for therapeutic formulations and methods for treating SARS-CoV-2 infections. The present disclosure, in some embodiments, provides novel compounds with dual targeting activity against SARS-CoV-2. The compounds selectively target the viral RdRp and Mpro enzymes and host TMPRSS2 protease.

Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.

Abstract: Compounds, compositions, and methods useful for treating a viral infection, such as human immunodeficiency virus (HIV) infection, are disclosed. In particular, 4?-thionucleoside analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.